Comparative Pharmacology
Head-to-head clinical analysis: CUBICIN versus CUBICIN RF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CUBICIN versus CUBICIN RF.
CUBICIN vs CUBICIN RF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cubicin is a lipopeptide antibiotic that binds to bacterial cell membranes, causing rapid depolarization and inhibition of protein, DNA, and RNA synthesis, leading to bacterial cell death.
Daptomycin is a cyclic lipopeptide antibiotic that binds to bacterial cell membranes, causing rapid depolarization and disruption of membrane potential, leading to cell death.
4-6 mg/kg IV once daily for complicated skin infections; 6 mg/kg IV once daily for Staphylococcus aureus bloodstream infections (including right-sided endocarditis); infuse over 2 minutes or 30 minutes.
Adults: 6 mg/kg IV over 30-60 minutes every 24 hours. For deep-seated infections (e.g., endocarditis, osteomyelitis), consider 10 mg/kg IV every 24 hours.
None Documented
None Documented
Terminal elimination half-life is about 8-9 hours (mean 8.1 hours) in patients with normal renal function; prolonged to 27-35 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life: approximately 8-9 hours in patients with normal renal function; prolonged in renal impairment.
Renal excretion of unchanged drug accounts for approximately 80% of the administered dose; minor fecal excretion (<5%) via biliary elimination.
Renal excretion: approximately 80% of the dose as unchanged drug; biliary/fecal elimination: minor (<5%).
Category C
Category C
Antibiotic
Antibiotic